429
Views
16
CrossRef citations to date
0
Altmetric
Research Article

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma

, , , , , , , , & show all
Pages 811-816 | Received 05 Apr 2013, Accepted 21 Jun 2013, Published online: 29 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Jean El Cheikh, Radwan Massoud, Basel Haffar, Elie Fares, Rami Mahfouz, Tamima Jisr, Mohamed A. Kharfan-Dabaja, Anas Mougharbel, Ali Youssef, Ali Bazarbachi & Ahmad Ibrahim. (2017) Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation. Leukemia & Lymphoma 58:11, pages 2745-2747.
Read now
Reyad Dada, Jamal Zekri & Rawan Al Saadi. (2016) Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opinion on Biological Therapy 16:6, pages 739-745.
Read now
Antonello Pinto, Paolo Corradini, Alberto Mussetti & Pier Luigi Zinzani. (2015) Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. Leukemia & Lymphoma 56:7, pages 1969-1974.
Read now

Articles from other publishers (13)

Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Malik E. Juweid, Kamal Al-Rabi, Mohammad Ma’koseh, Hikmat Abdel-Razeq & Asem Mansour. (2023) FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects. Cancers 15:4, pages 1063.
Crossref
Aglaia Schiza, Sandra Irenaeus, Francisco Ortiz-Nieto, Angelica Loskog, Thomas Tötterman, Anders Sundin, Gustav J. Ullenhag & Håkan Ahlström. (2019) Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. Scientific Reports 9:1.
Crossref
Jan Maciej Zaucha, Stephane Chauvie, Renata Zaucha, Alberto Biggii & Andrea Gallamini. (2019) The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treatment Reviews 77, pages 44-56.
Crossref
P.L. Zinzani, S. Sasse, J. Radford, A. Gautam & V. Bonthapally. (2016) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Critical Reviews in Oncology/Hematology 104, pages 65-70.
Crossref
Michael Coyle, Lale Kostakoglu & Andrew M. Evens. (2016) The evolving role of response-adapted PET imaging in Hodgkin lymphoma. Therapeutic Advances in Hematology 7:2, pages 108-125.
Crossref
Andrea Gallamini, Anna Borra & Colette Zwarthoed. 2016. PET Scan in Hodgkin Lymphoma. PET Scan in Hodgkin Lymphoma 31 64 .
Pier Luigi Zinzani, Cinzia Pellegrini, Maria Cantonetti, Alessandro Re, Antonello Pinto, Vincenzo Pavone, Luigi Rigacci, Melania Celli, Alessandro Broccoli, Lisa Argnani & Alessandro Pulsoni. (2015) Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. The Oncologist 20:12, pages 1413-1416.
Crossref
Pier Luigi Zinzani, Paolo Corradini, Alessandro M. Gianni, Massimo Federico, Armando Santoro, Umberto Vitolo, Giovanni Barosi & Sante Tura. (2015) Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. Clinical Lymphoma Myeloma and Leukemia 15:9, pages 507-513.
Crossref
Pier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, Paolo Corradini, Giovanna Motta, Monica Tani, Nicola Cascavilla, Stefan Hohaus, Francesco Merli, Lisa Argnani & Alessandro Broccoli. (2015) Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. Clinical Lymphoma Myeloma and Leukemia 15:7, pages 404-408.
Crossref
Andrea Gallamini, Martin Hutchings & Anna Borra. 2015. Hodgkin Lymphoma. Hodgkin Lymphoma 107 130 .
Solomon A. Graf & Ajay K. Gopal. (2014) Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. Hematology 2014:1, pages 151-157.
Crossref
Andrew M. Evens & Lale Kostakoglu. (2014) The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology 2014:1, pages 135-143.
Crossref
Andrew M. Evens & Lale Kostakoglu. (2014) The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Blood 124:23, pages 3356-3364.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.